RASSF2 is a tumour suppressor that in common with the rest of the RASSF family contains Ras association and SARAH domains. We identified the proapoptotic kinases, MST1 and MST2, as the most significant binding partners of RASSF2, confirmed the interactions at endogenous levels and showed that RASSF2 immunoprecipitates active MST1/2. We then showed that RASSF2 can be phosphorylated by a co-immunoprecipitating kinase that is likely to be MST1/2. Furthermore, we showed that RASSF2 and MST2 do indeed colocalize, but whereas RASSF2 alone is nuclear, the presence of MST1 or MST2 results in colocalization in the cytoplasm. Expression of RASSF2 (stably in MCF7 or transiently in HEK-293) increases MST2 levels and knockdown of RASSF2 in HEK-293 cells reduces MST2 levels, in addition colorectal tumour cell lines and primary tumours with low RASSF2 levels show decreased MST2 protein levels. This is likely to be mediated by RASSF2-dependent protection of MST2 against proteolytic degradation. Our findings suggest that MST2 and RASSF2 form an active complex in vivo, in which RASSF2 is maintained in a phosphorylated state and protects MST2 from degradation and turnover. Thus, we propose that the frequent loss of RASSF2 in tumours results in the destablization of MST2 and thus decreased apoptotic potential.
Introduction
The RASSF family of proteins comprises 10 members all sharing a region of homology, the ras association domain. The classical RASSFs (RASSF1-6) contain, in addition, a SARAH domain, so named for its original identification in Sav (the Drosophila WW45 orthologue), RASSF and Hippo (the Drosophila MST orthologue) (Scheel and Hofmann, 2003) . The best studied member of the RASSF family, RASSF1A, is important for cellcycle regulation, apoptosis and microtubule stability (Agathanggelou et al., 2005) . Although rarely mutated, RASSF1A is frequently inactivated by promoter methylation in a wide range of tumour types (Agathanggelou et al., 2005) and has recently been shown to be degraded by calpain-mediated proteolysis (Kuznetsov and Khokhlatchev, 2008) . The more recently discovered and less well-characterized RASSF2 has also been shown to be frequently inactivated by promoter methylation in a wide range of tumour types, including colorectal (Hesson et al., 2005) , gastric (Endoh et al., 2005) , oral , endometrial (Liao et al., 2008) , breast and lung (Kaira et al., 2007; Cooper et al., 2008) . RASSF2 has been shown to inhibit the growth of lung (Vos et al., 2003) and breast (Cooper et al., 2008) cancer cell lines, both in vitro and in vivo. We and others (Kumari et al., 2007; Cooper et al., 2008; Maruyama et al., 2008) have described the RASSF2 nuclear localization signal and showed that a functional NLS is required for full tumour suppressor activity. To further understand the function of RASSF2, we made use of proteomic approaches to determine RASSF2 binding partners.
MST1 (STK4/KRS2) and MST2 (STK3/KRS1) are members of the GCKII subclass of sterile 20 proapoptotic kinases, they contain an amino-terminal kinase domain separated from a C-terminal inhibitory domain by caspase cleavage sites. Full-length MST1 and MST2 are predominantly cytoplasmic because of the presence of carboxy-terminal nuclear export signals (Ura et al., 2001) , but nuclear accumulation is observed after treatment with Leptomycin B (a nuclear export inhibitor) showing that MSTs perpetually shuttle through the nucleus (Lee et al., 2001; Ura et al., 2001; Lee and Yonehara, 2002; Lin et al., 2002) . Kinase activity is regulated by autophosphorylation, caspase cleavage and possibly dimerization and co-factor binding. Autophosphorylation at threonine in the context KRNT (MST1 T183, MST2 T180) is essential for full kinase activity (Glantschnig et al., 2002; Deng et al., 2003) and may influence susceptibility to cleavage . MST1 contains caspase cleavage sites at amino acids 326 and 349 ; Lee et al., 2001) , cleavage can be induced by CD95/Fas (Graves et al., 1998) , anticancer drugs (Kakeya et al., 1998) or biphosphonates (inducers of osteoclast apoptosis) (Reszka et al., 1999) . Cleavage by caspases separates the MST kinase and inhibitory domains (Graves et al., 1998 ; Lee et al., 2001) resulting in nuclear accumulation of the kinase domain (Lee et al., 2001; Ura et al., 2001) , in which it can phosphorylate histone H2B at Ser 14 (Cheung et al., 2003) resulting in chromatin condensation and apoptosis; however, recent reports suggest that JNK activation, and not H2B phosphorylation, is essential for chromatin condensation (Hu et al., 2007; Ura et al., 2007) . It has been proposed (Deng et al., 2003) that in normal cells autophosphorylation is reversible by protein phosphatases resulting in the majority of MST protein being unphosphorylated. However, in cells undergoing apoptosis, caspase-3-dependent cleavage of MST and irreversible autophosphorylation results in an accumulation of active MST.
In common with the RASSF family of proteins, MST1 and MST2, contain a SARAH domain located at the C terminus. This domain is essential for dimerization (Creasy et al., 1996) and binding to RASSF1 or NORE1 Rabizadeh et al., 2004; Oh et al., 2006) . The addition of purified RASSF1A or NORE1A to MST1 inhibits kinase activity in vitro (Praskova et al., 2004; Rabizadeh et al., 2004; Oh et al., 2006; Guo et al., 2007) . In contrast, in cells, induction of MST1 membrane localization through membranebound NORE or myristoylation augments its apoptotic efficiency Praskova et al., 2004) . However, the picture in cells without forced membrane localization is less clear; decreased MST1 phosphorylation in cells after coexpression of MST1 with RASSF1A, F1C, NORE1A or 1B was observed Praskova et al., 2004) ; however, increased phosphorylation of MST2 or MST1 after RASSF1A transfection has also been shown (Rabizadeh et al., 2004; Oh et al., 2006; Guo et al., 2007) . These differences could be due to differing experimental protocols, but may well reflect the presence of other factors that are available to be recruited. Depending on which factors are in the complex RASSF1A may be able to switch between activation and inhibition. Thus, RASSF family members may act as versatile scaffolds for bringing together MSTs, their regulators and substrates, and possibly different RASSFs may bring along different regulators and or substrates. Therefore, after we identified MST1 and MST2 as the significant binding partners of RASSF2, we deemed it important to determine the specific properties of the RASSF2 MST interacting unit.
Results
In a yeast two-hybrid screen, RASSF2 interacts with several proteins including MST1 implicated in mediating apoptosis A yeast two-hybrid screen was performed with RASSF2 as bait. Interactions that were validated by yeast co-transformations included those with members of the RASSF family (RASSF3 and NORE1), Filamin C (an actin-binding protein that when mutated can cause autosomal dominant myofibrillar myopathy), C14ORF2 (a protein of unknown function), Secretogranin III (a neuroendocrine secretory protein) and MST1 (a proapoptotic kinase also known as STK4). The MST1/2 association was the most interesting, given the roles of MST1 and MST2 in apoptosis. However, there was little information about the other interacting proteins to help placing the putative association in the context of apoptotic cell signalling. Therefore, we performed the FLAG-immunoprecipitation/mass spectrometry analysis in an effort to find more RASSF2-interacting proteins.
MST1 and MST2 are the most significant binding partners of RASSF2 in a FLAG-immunoprecipitation/ mass spectrometry analysis We have generated clones stably expressing FLAGtagged RASSF2 (Cooper et al., 2008) in the MCF7 cell background, in which endogenous RASSF2 expression is silenced through promoter methylation. From these cells, we used FLAG immunoprecipitation to enrich for proteins binding to RASSF2. The immunoprecipitate was eluted with FLAG peptide and resolved through a polyacrylamide gel (Figure 1a) . The gel was then cut into sections and each section was digested with trypsin, and peptides were analysed by mass spectrometry. The list of potential interactors was headed by the mammalian ste20-like kinases 1 and 2 (MST1 and MST2). Next to the bait protein they were the strongest band, and peptide coverage of these proteins was 29.8% for MST1 and 52.1% for MST2 (Figure 1b) . Endogenous MST1 and MST2 and RASSF2 co-immunoprecipitate, and their interaction is mediated through the RASSF2 SARAH domain In order to verify that the interaction between MST1 or MST2 and RASSF2 was not an experimental artefact of FLAG-RASSF2 overexpression, the data were confirmed in reverse using FLAG-tagged MST1 or MST2 to immunoprecipitate endogenous RASSF2 (data not shown). To show that these interactions were not mediated by the FLAG tag, endogenous RASSF2 was immunoprecipitated from A549 cells (a cell line that we have shown expresses high levels of RASSF2 by reverse transcriptase-PCR, and that by reverse transcriptase-PCR the levels of RASSF2 do not change with treatment with the demethylating agent 5-aza-2 0 deoxycytidine) and endogenous MST1 and MST2 shown to coprecipitate (Figure 2a ). The reciprocal experiment showed that antibodies against endogenous MST1 or MST2, but not IgG alone, precipitated RASSF2 ( Figure 2b ). Immunoprecipitation of RASSF2 from A549 shows that the majority of MST1 and a large fraction of MST2 present in the cell were found in complex with RASSF2 ( Figure 2c ). Similar data were also obtained in HEK-293 cells.
In order to map the interaction domains, constructs of RASSF2 were generated that deleted amino acids 249-end, or 108-253. These constructs partially delete the RA domain and all of the SARAH domain or the NLS and most of the RA domain, respectively (Figure 3a) . Cotransfection of GFP-tagged RASSF2 with FLAG-tagged MST1 or MST2 into HEK-293 cells followed by FLAG immunoprecipitation showed interactions between MST1 or MST2 and full-length RASSF2 and RASSF2 D108-253, but not with amino acids 1-248 (Figures 3b-c) , suggesting that the interaction is likely to be mediated through the RASSF2 SARAH domain. Therefore, we mutated a leucine (conserved between RASSF family members and MSTs from a variety of species, including human, mouse and Xenopus) within the SARAH domain (L290) to proline, this alteration greatly reduced the interaction between RASSF2 and MST2, and abolished the interaction between RASSF2 and MST1 ( Figure 3d ). This residue is also important for RASSF2 dimerization as RASSF2 L290P is substantially less able to immunoprecipitate GFP-tagged RASSF2 (Supplementary Figure S1) . In addition to wild-type MST1/2, kinase inactive (K56R) and non-phosphorylatable (T183A, T180A) mutants of MST1 and MST2 also immunoprecipitated RASSF2 (Figures 3b-c) . Thus, RASSF2 interacts with both MST1 and MST2, and kinase null and non-phosphorylatable mutants of MST1/2, and the interaction is mediated by the RASSF2 SARAH domain.
RASSF2 immunoprecipitates active MST
Immunoprecipitation of RASSF2 showed that RASSF2 interacts with both wild-type MST1 and MST2 and kinase-inactive (MST2 K56R) and non-activatable mutants (MST1 T183A, MST2 T180A), suggesting that full activity of MST1/2 is not a prerequisite for the interaction to occur. In order to determine whether RASSF2 was sequestering MST1 and MST2 in an inactive form and as such involved in the regulation of MST activity, we transfected HEK-293 cells with FLAG-tagged RASSF2 then treated the cells with the phosphatase inhibitor okadaic acid (OA), which is 
MST2 IgG
Figure 2 Endogenous MST1 and MST2 immunoprecipitate with endogenous RASSF2, and the majority of endogenous MST1 and MST2 is bound to endogenous RASSF2 in mammalian cells. To investigate, whether endogenous RASSF2 interacts with endogenous MST1 or MST2, we immunoprecipitated MST1, MST2 and RASSF2 from A549 cells. In immunoprecipitates of RASSF2, both MST1 and MST2 were detected (a), and RASSF2 co-immunoprecipitated with both MST1 and MST2 (b). *corresponds to IgG heavy chain. To ascertain what fraction of endogenous MST1 or MST2 is associated with endogenous RASSF2, we immunodepleted RASSF2 from A549 protein lysates and immunoblotted the RASSF2-bound and unbound fractions (c; I is input, s/n supernatant, and B bound fraction. b-actin was included to control for equal loading of input and supernatant and to control for specificity of the immunoprecipitaion). Thus, the majority of both MST1 and MST2 co-immunoprecipitate with RASSF2. Figure 1 MST1 and MST2 are major interacting partners of RASSF2 in mammalian cells. FLAG-tagged RASSF2 was immunoprecipitated from stably transfected MCF7 cells and interacting partners were resolved by electrophoresis through a 10% acrylamide gel (a). The gel was cut into 12 sections and each analysed by electrospray ESI-QUAD-TOF mass spectrometry, the resulting list of peptides was pooled and used for searching the SwissProt and NCBI databases. In addition to RASSF2, the most significant interacting partners were MST1 and MST2 with 29.8 and 52.1% peptide coverage (b), identified peptides are depicted in bold.
RASSF2 binds and stabilizes MST2 WN Cooper et al known to activate MST. Incorporation of g-32 P ATP was used to determine the FLAG-associated kinase activity. Phosphorimaging of the gel showed two differently sized substrates for 32 P incorporation corresponding in size to MST1/2 and RASSF2 (Figures 4a  and b ), indicating that RASSF2 was a substrate for MST1/2 phosphorylation. The band corresponding to the autoradiograph was excised (Figure 4b ) and subjected to electron capture dissociation FT-ICR mass spectroscopy using an LTQ-FT mass spectrometer (Thermo Scientific, Waltham, MA, USA); this confirmed the presence of both phosphorylated and unphosphorylated peptides of RASSF2. Subdivision of the kinase reaction into two fractions corresponding to the portion of proteins that remained bound to MST2 throughout the kinase reaction and those proteins that dissociated during the reaction indicated that phosphorylation of RASSF2 does not induce its dissociation from MST2 (Supplementary Figure S2) . Similar experiments performed with cotransfected FLAG-MST2-K56R (kinase dead mutant) resulted in undetectable levels of 32 P incorporation (data not shown) indicating that MST2 is inducing the phosphorylation.
RASSF2 can stabilize MST2
Interestingly, although the amount of MST2 immunoprecipitating with FLAG-RASSF2 remains constant (or perhaps increases, Figure 4a ) total MST2 diminishes in lysates after OA treatment, suggesting that activation of MST2 may induce its degradation. In addition, cotransfection of GFP-RASSF2 with FLAG-MST2 resulted in much higher levels of FLAG-MST2 expression than when FLAG-MST2 was cotransfected with RASSF2 deletions (Figure 3c ). Thus, we hypothesized that RASSF2 was protecting MST2 protein. To test this hypothesis, we compared MCF7 cells that lack RASSF2 protein with MCF7 cells stably expressing RASSF2.
MCF7 cells stably expressing RASSF2 have consistently higher levels of MST2 than MCF7 cells transfected with empty vector (Figure 5a ). Treatment with . Deletion constructs of RASSF2 were generated deleting the SARAH domain (hatched) or RA (black) (a). HEK-293 were transfected with FLAG-tagged MST1 or MST2 or mutants, and GFP-tagged RASSF2. Lysates were precipitated with anti-FLAG-agarose, and the precipitating proteins immunoblotted for GFP (b, c). Alternatively FLAG-tagged RASSF2 or RASSF2 L290P were cotransfected with HA-tagged MST1 or MST2, precipitated with anti-FLAG-agarose, and the precipitating proteins immunoblotted for HA (d). agents that induce apoptosis (staurosporine or OA) could increase this difference by reducing the levels of MST2 by a greater extent in cells lacking RASSF2 than in cells expressing RASSF2. Thus, RASSF2 may protect MST2 from degradation or RASSF2 may induce MST2 expression. Next, we looked at HEK293 cells transiently transfected with RASSF2 and/or MST2 (Figure 5b ). In these experiments, RASSF2 was able to increase MST2 protein levels of both endogenous and CMV promoterdriven HA-tagged MST2 showing that this effect was not mediated at the level of transcription. In addition, the mutant of RASSF2 with diminished ability to bind MST2 (RASSF2 L290P) showed a reduced ability to stabilize MST2 (data not shown). Knockdown of RASSF2 expression in HEK-293 and HCT116 cell lines with siRNA directed against RASSF2 resulted in decreased levels of MST2 and also MST1 (Figure 5c ). Thus, RASSF2 may play a role in protection of MST2 in cells and loss of RASSF2 by promoter methylation, as is frequently observed in human tumours (Hesson et al., 2005; Cooper et al., 2008) , may result in destablization of MST2. Therefore, we analysed a series of human colon cancer cell lines for the expression of RASSF2 and MST2. We observed a correlation between the levels of RASSF2 and MST2 protein expression; for example, the cell line HCT116 that expresses RASSF2 also expresses higher levels of MST2 than the cell lines that do not express RASSF2 (Figure 5d ). In addition, we investigated whether loss of RASSF2 protein correlated with reduced levels of MST2 in primary colorectal carcinomas. In all, 12 samples were analysed. We found four tumours expressed higher levels of both RASSF2 and MST2 (for example, tumours 39 and 97, Figure 5e ), whereas seven tumours displayed vastly reduced or undetectable levels of either protein (for example, tumours 14, 13 and 43, Figure 5e ). In only one of the twelve tumours there were high levels of MST2 in the absence of RASSF2.
In order to study the effect of the protein phosphatase inhibitor OA, HEK-293 cells were treated with OA for various periods of time (Figure 6a ). Treatment with OA substantially diminished total MST2 by 3 h. This was not accompanied by appearance of the N-terminal cleavage product (Figure 6a ) suggesting that this reduction was not a result of MST2 cleavage. Therefore, we postulated that activation of MST2 by OA can induce its degradation and that RASSF2 may protect MST2 from this degradation. One potential mediator of this degradation is the proteasome, and to test whether OA was inducing proteasome-mediated degradation of MST2, we pre-treated HEK-293 cells with the proteasome inhibitor, MG132 for 1 h, followed by treatment with OA for a further 3 h. Treatment with MG132 at concentrations between 10 and 50 mM could restore MST2 to levels similar to that observed without OA (Figure 6b ) indicating that degradation of MST2 in response to OA is indeed mediated through the proteasome. Transfection of FLAG-RASSF2 was also able to partially rescue the OA-induced decrease in levels of MST2, again suggesting that RASSF2 has a protective effect on MST2 (Figure 6b ). The effect of expression of FLAG-RASSF2 is weaker in HEK-293 cells than in MCF7 cells and this is probably because of the presence of sufficient endogenous RASSF2 in HEK-293 cells to stabilize the majority of endogenous MST2.
RASSF2 and MST1 or MST2 colocalize in the cytoplasm
In order to better understand the functional relevance of these interactions, we cotransfected RASSF2 and MST1/2 into Cos7 cells. MST1 or MST2 alone were predominantly cytoplasmic, and RASSF2 alone was predominantly nuclear. However, when cotransfected with MST1 or MST2, RASSF2 became relocalized to the cytoplasm (Po0.0001 for FLAG vs FLAG-MST1; Po0.0001 for FLAG vs FLAG-MST2, Figure 7) . The RASSF2 mutant with the SARAH domain deleted (RASSF2 1-248) was resistant to this translocation (Figure 7) . Interestingly, mutants of MST2 were unable to induce this relocalization with the kinase dead mutant, K56R, and the non-phosphorylatable mutant, T180A, leaving RASSF2 predominantly nuclear (Po0.0001 for FLAG-MST2 vs FLAG-MST2 K56R; Po0.0001 for FLAG-MST2 vs FLAG-MST2 T180A, Figure 7 ). Immunoprecipitation (Figures 3b-c) showed that these mutants bound RASSF2 equally well suggesting that the mutants are not held in an alternative conformation that binds RASSF2 less well. This suggests that only fully active MST can induce translocation of RASSF2. As kinase assay suggests that MST1/2 can phosphorylate RASSF2, we postulate that phosphorylation of RASSF2 may alter its properties overcoming the function of the RASSF2 nuclear localization signal (Kumari et al., 2007; Cooper et al., 2008; Maruyama et al., 2008) and enabling RASSF2 to be translocated to the cytoplasm. Figure 7 MST translocates RASSF2 to cytoplasm. (a) Cos7 cells were cotransfected with GFP-RASSF2 and either empty FLAG or FLAG-tagged MST1 or MST2 or mutants, after 48 h cells were fixed and stained with an anti-FLAG antibody and the number of cells exhibiting predominantly nuclear or predominantly cytoplasmic localization determined. Three representative fields of view are shown for each transfection. The left panels show the composite images from red, blue and green channels whereas the right panels show the green channel of the same region. This figure is available in colour in the online HTML version. (b) above data depicted as a pie chart.
Discussion
Yeast two-hybrid and FLAG-immunoprecipitation mass spectrometry-based interaction screens indicated that the proapoptotic kinases, MST1 and MST2, were the most significant RASSF2-interacting partners. Although it had previously been shown that MST1 and MST2 can interact with NORE1A, NORE1B, RASSF1A and RASSF1C Praskova et al., 2004; Hwang et al., 2007) , no previous characterization of the interaction between endogenous RASSF2 and endogenous MST1/2 has been reported. First, we showed (Figure 2 ) that RASSF2 can co-immunoprecipitate endogenous MST1 and MST2, and also that antibodies against MST1 or MST2 can coprecipitate endogenous RASSF2. Deletion and mutagenesis of RASSF2 showed that this interaction was indeed mediated through the RASSF2 SARAH domain as is the case for RASSF1A and NORE1 .
Inspection of the Coomassie stained gel of proteins coprecipitating with RASSF2 ( Figure 1a ) suggested that two of the three most intensely staining bands were the correct sizes to be RASSF2 and MST1/2. This and the huge significance with which MST1 and MST2 peptides were identified by mass spectroscopy suggested that the RASSF2-MST complex was very abundant and possibly that the majority of MST1 and MST2 present in the cells was in complex with RASSF2. Thus, we compared the amount of MST1 and MST2 present in lysates from untransfected cells with the amount remaining unbound in the supernatant after immunoprecipitation of RASSF2. This showed that the vast majority of MST1 and most of the MST2 in A549 or HEK-293 cells was present in complex with RASSF2. This suggests that RASSF2 is a more significant binding partner of MST1 and MST2 than NORE1 or RASSF1, because MST1 only immunoprecipitates substoichiometric amounts of NORE1/RASSF1A (Praskova et al., 2004) , perhaps this is because the rest of the MST1 is bound to RASSF2. This demonstration that the majority of MST1 and MST2 in cells are present in complex with RASSF2, is in accordance with size exclusion chromatography, which indicated that wild-type MST1 and monomeric MST1 (that is, SARAH domain mutant L444P) were present in higher-molecular-weight complex (250 and 130 kDa, respectively) than would be predicted from their amino acid composition (predicted monomer 55.6 kDa) (Creasy et al., 1996; Lee and Yonehara, 2002) .
As RASSF2 was present in complex with the majority of cellular MST1 and MST2, it was important to determine whether RASSF2 was specifically sequestering an inactive subset of MST, thus, we used kinase assay to show that the RASSF2-associated MST1/2 was both able to phosphorylate itself and interestingly could phosphorylate RASSF2 in a manner analogous to that seen for Sav (Callus et al., 2006) .
Given the documented cellular localization of RASSF2 as nuclear (Kumari et al., 2007; Cooper et al., 2008; Maruyama et al., 2008) and MST2 as cytoplasmic (Lee et al., 2001; Ura et al., 2001; Lee and Yonehara, 2002) , it was perhaps surprising that that they coimmunoprecipitated. However, we found that cotransfection of RASSF2 with MST2 resulted in the translocation of RASSF2 from the nucleus to the cytoplasm, and that this relocalization was dependent on the ability of the two proteins to interact because deletion of the SARAH domain from RASSF2 (which abolished their interaction) prevented the MST-induced relocalization of RASSF2. The MST kinase activity was also essential for this relocalization, suggesting that perhaps MST1/2 binds to RASSF2 through their common SARAH domains and phosphorylates RASSF2 inducing RASSF2 relocalization. Therefore, we postulate that hyperphosphorylation of RASSF2 induces its nuclear-cytoplasmic translocation. Since MST1 and MST2 are known to cycle through the nucleus (Lee et al., 2001; Ura et al., 2001; Lee and Yonehara, 2002; Lin et al., 2002) , it is possible that they can encounter RASSF2 in the nucleus, bind to it and induce its translocation to the cytoplasm, where RASSF2 remains only when it becomes hyperphosphorylated. This phosphorylation of RASSF2 may be facilitated by apoptotic activation of MST1/MST2 either physiologically or constitutively by overexpressioninduced autophosphorylation (Glantschnig et al., 2002; Deng et al., 2003) . Therefore, it is possible that RASSF2 may act as a scaffold maintaining things in the nucleus and transporting them to the cytoplasm during MST-mediated apoptosis.
Stable expression of RASSF2 in the MCF7 cell line (that lacks endogenous RASSF2 expression because of promoter methylation) caused an increase in MST2 protein levels when compared with equivalent cells transfected with the empty vector, whereas treatment with OA decreased the levels of MST2. Furthermore, we showed that knockdown of RASSF2 in cell lines resulted in decreased levels of MST2 protein and in colorectal tumours, reduced RASSF2 protein levels correlated with reduced MST2 proteins levels. The decrease in MST2 levels was not because of cleavage of MST2, and was instead likely to be due to proteasome-mediated degradation because pretreatment with the inhibitor of proteasome-mediated degradation MG132 could in part prevent the decrease in MST2 levels. In addition, expression of RASSF2 could partially protect MST2 from OA-mediated degradation. We present the following evidence: (i) RASSF2 is a major interacting partner of both MST1 and MST2; (ii) Activation of MST2 results in its increased turnover by proteasomal degradation; (iii) The presence of RASSF2 protects MST2 from degradation; (iv) Active MST2 can phosphorylate RASSF2; and (v) Active MST2 can relocalize RASSF2 from the nucleus to the cytoplasm and the kinase activity of MST2 is essential for this relocalization. From these data, we propose the following hypothesis. In the presence of RASSF2, proapoptotic stimuli that result in the activation of MST2 allow the cytoplasmic accumulation of the RASSF2-MST complex. In the absence of RASSF2, activation of MST2 results in its rapid degradation, nullifying its effects as a proapoptotic protein. This may explain the induction of apoptosis observed on reexpression of RASSF2 in cell lines lacking expression (Vos et al., 2003) . Therefore, loss of RASSF2 in cancer RASSF2 binds and stabilizes MST2 WN Cooper et al cells after promoter hypermethylation can cause a decrease in MST2 stability and thus decreased apoptotic potential.
Materials and methods

Expression constructs
Full-length RASSF2 (NM_014737) was amplified by PCR using the primers CTT ATC GCG GCC GCG atg gac tac agc cac caa acg and CT TAT TCT AGA tca gat tgt tgc tgg ggt ctc and cloned between the NotI and XbaI sites of p-FLAG-CMV4 vector (Sigma-Aldrich, St Louis, MO, USA). RASSF2 was also cloned between the BglII and SalI sites of EGFP-C2 (destroying the BglII site in the process). Deletion constructs were then generated by restriction digestion and re-ligation; ApaI was used to delete amino acids from 249 to end and BglII deleted amino acids 108-253. The QuikChange Lightning site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands) was used to mutate pFLAG-RASSF2. To generate the L290P mutation, the mutagenic primers were gcttcattcagaagcCccaggaggaagaaga and tcttcttcctcctggGgcttctgaatgaagc. Expression constructs for FLAG-MST1 or MST2 and mutants of MST1 and MST2 were described previously (O'Neill et al., 2004) . The sequence of constructs was verified by sequencing using fluorescent dye terminators (BigDye V3.1 Applied Biosystems, Foster City, CA, USA).
Antibodies
Mouse monoclonal antibodies against FLAG (M2, F-1804), b-actin (A-5441) and HA (H-9658) were from Sigma-Aldrich. Rabbit polyclonal anti-HA (sc-805), anti-GFP (sc-8334) and goat polyclonal anti RASSF2 (sc-46475 for characterization see Figure 5c and Supplementary Figure S3 ) and anti MST1 (sc-6088) antibodies were from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Rabbit polyclonal antibody to a-tubulin (ab18251), and rabbit monoclonal antibody against STK3 (MST2, ab52641) were from Abcam, Cambridge, UK. Rabbit polyclonal antibodies against MST1 (#3682), MST2 (#3952) and phosphorylated MST (#36815) were from Cell Signaling, Danvers, MA, USA. HRP-conjugated Rabbit anti-mouse IgG (P0161) and normal control goat and rabbit IgG were purchased from DAKO, Glostrup, Denmark. HRP-conjugated goat antirabbit IgG (31462) was from Pierce, Rockford, IL, USA. Alexafluor-594-conjugated rabbit anti-mouse IgG (A11005) was purchased from Invitrogen, Paisley, UK.
Cell lines and transfection HEK-293, Cos7, MCF7 and colorectal tumour (DLD1, HCT116, SW620, 147T, LS411) cell lines were grown in DMEM supplemented with 10% FCS and L-glutamine and were routinely maintained at 37 1C and 5% CO 2 . Clones of the breast tumour cell line, MCF7 stably expressing FLAG-RASSF2, have been described previously (Cooper et al., 2008) .
Cos7 cells seeded on glass coverslips in six-well plates were transfected with 1 mg plasmid DNA using 3 ml FuGENE 6 (Roche, Basel, Switzerland). At 48 h later, cells were fixed and immunostained according to Dallol et al. (2004) . Images of at least 25 randomly selected cells stained for both GFP and FLAG were captured then scored for the localization of the green fluorescence according to the following criteria: 'Mostly nuclear' indicates that either all or most of the green signal colocalized with the blue DAPI nuclear stain. 'Equal' signified equal staining in nucleus and cytoplasm. 'Mostly cytoplasmic' indicated that either all or most of the green signal localized in the cytoplasm.
RNA interference was performed using LipoFECTAMINE (Invitrogen) with 5 ng of RASSF2 small-interfering RNA (Ambion oligo ID number 21809; Ambion, Austin, TX, USA), or scrambled oligo following the manufacturer's instructions. At 24 h later, the cells were re-transfected with HiPerFect (Qiagen, Crawley, UK) again with 5 ng of siRNA. The cells were lysed the next day.
HEK-293 cells were transfected using polyethylenimine (Polysciences Warrington, PA, USA) according to Durocher et al. (2002) . At 48 h after transfection, where indicated cells were treated with 1 mM Staurosporine (Sigma-Aldrich), 1 mM OA and/ or MG132 (Merck Biosciences, Darmstadt, Germany) for the times described and then lysed in 1% Triton 100 Â , 50 mM NaF, 50 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 5 mM Na-pyrophosphate, 1 mM Na-vanadate, 0.27 M sucrose with complete, mini, EDTA-free protease inhibitor cocktail tablet (Roche).
Primary tumour samples
For analysis of protein expression in primary colorectal tumours, we homogenized each 100 mg of tissue in the presence of 300 ml cell lysis buffer (as above, but supplemented with 200 mM NaCl). Samples were then incubated at 4 1C for 30 min with end-overend mixing followed by centrifugation for 10 min at 13 000 r.p.m. at 4 1C. A total of 30 mg of total protein (equivalent to 1.6 mg of tissue) was then subjected to SDS-PAGE, transferred to PVDF membrane and probed for the presence of RASSF2, MST2 and b-actin. Tumour samples were collected with approval from the local ethics committee following the institutional guidelines. Ethics approval number 02/022. Immunoprecipitation Lysate (1 mg) was incubated with 4 mg of antibody or an equivalent amount of the appropriate preimmune IgG and 8 ml Protein G Sepharose (Sigma-Aldrich) or anti-FLAG M2 affinity gel (Sigma-Aldrich). After 1 h and 30 min, lysate was transferred to a SpinX column (Corning, Schiphol-Rijk, The Netherlands) and beads washed thrice with lysis buffer supplemented with 150 mM NaCl. A final wash was performed with 50 mM Tris, 0.1 mM EGTA, before elution with gel loading buffer.
Kinase assay
Using anti-FLAG M2 affinity gel (Sigma-Aldrich) FLAG-RASSF2 was immunoprecipitated from 1 mg cell lysate. After washing, the FLAG-agarose beads were incubated with kinase assay buffer (50 mM Tris-HCl pH 7.5, 0.1% b-mercaptoethanol, 1 mM EGTA, 10 mM magnesium acetate and 1 mM ATP containing 0.5 uCi g 32 P) and incubated at 30 1C for 30 min with vigorous shaking. The reaction was then terminated by addition of SDS sample loading buffer and subjected to SDS-PAGE. The gel was then fixed and 32 P detected by phosphorimaging. Alternatively, the kinase assay was performed in the absence of 32 P, bands excised from Coomassie stained gel and phosphorylation identified by FT-ICR mass spectrometry at University of Birmingham Functional Genomics and Proteomics Unit.
Identification of novel interacting partners
Yeast two-hybrid screen was performed as described previously . Immunoprecipitation and identification using 2D-LC/MS/MS was done as described (von Kriegsheim et al., 2006) with minor modifications.
Statistical analysis
Statistical significance was assessed using the w 2 -test.
